Table 3 Clinical characteristics of patients with GC/GEJC/EAC, HER2 status negative/unknown, on first-line treatment
Disease status | Total | France | Germany | UK | US | Japan | China |
|---|---|---|---|---|---|---|---|
n = 682 | n = 168 | n = 146 | n = 145 | n = 99 | n = 36 | n = 88 | |
Time since initial diagnosis, months | 625 | 156 | 135 | 129 | 86 | 31 | 88 |
 Mean (SD) | 6.3 (13.0) | 6.2 (10.0) | 5.3 (6.2) | 3.3 (3.4) | 6.4 (13.2) | 10.3 (12.4) | 11.3 (26.3) |
 Median (IQR) | 3 (2–6) | 3 (2–5) | 3 (2–5) | 2 (2–4) | 3 (2–5) | 6 (2–11) | 6 (3–14) |
Time since advanced diagnosis, months | 629 | 155 | 139 | 129 | 87 | 31 | 88 |
 Mean (SD) | 4.8 (7.6) | 4.5 (7.1) | 4.8 (5.6) | 3.1 (3.1) | 6.0 (13.1) | 8.5 (9.6) | 5.0 (7.1) |
 Median (IQR) | 3 (2–5) | 3 (2–4) | 3 (2–5) | 2 (2–3) | 3 (2–5) | 6 (2–10) | 3 (2–5) |
ECOG at advanced diagnosis, n (%) | 679 | 168 | 143 | 145 | 99 | 36 | 88 |
 0 | 98 (14.4) | 21 (12.5) | 8 (5.6) | 31 (21.4) | 11 (11.1) | 15 (41.7) | 12 (13.6) |
 1 | 421 (62.0) | 101 (60.1) | 100 (69.9) | 102 (70.3) | 58 (58.6) | 15 (41.7) | 45 (51.1) |
 2 | 152 (22.4) | 45 (26.8) | 35 (24.5) | 12 (8.3) | 23 (23.2) | 6 (16.7) | 31 (35.2) |
Current ECOGa, n (%) | 682 | 168 | 146 | 145 | 99 | 36 | 88 |
 0 | 73 (10.7) | 13 (7.7) | 6 (4.1) | 27 (18.6) | 12 (12.1) | 9 (25.0) | 6 (6.8) |
 1 | 388 (56.9) | 92 (54.9) | 76 (52.1) | 105 (72.4) | 58 (58.6) | 19 (52.8) | 38 (43.2) |
 2 | 221 (32.4) | 63 (37.5) | 64 (43.8) | 13 (9.0) | 29 (29.3) | 8 (22.2) | 44 (50.0) |
ECOG changeb, n (%) | 672 | 167 | 138 | 145 | 99 | 36 | 87 |
 Unchanged | 510 (75.9) | 132 (79.0) | 96 (69.6) | 129 (89.0) | 80 (80.8) | 24 (66.7) | 49 (56.3) |
 Changed | 162 (24.1) | 35 (21.0) | 42 (30.4) | 16 (11.0) | 19 (19.2) | 12 (33.3) | 38 (43.7) |
TNM staging at advanced diagnosis, n (%) | 682 | 168 | 146 | 145 | 99 | 36 | 88 |
 Stage IIIA | 74 (10.9) | 6 (3.6) | 28 (19.2) | 3 (2.1) | 10 (10.1) | 1 (2.8) | 26 (29.6) |
 Stage IIIB | 79 (11.6) | 8 (4.8) | 28 (19.2) | 2 (1.4) | 9 (9.1) | 1 (2.8) | 31 (35.2) |
 Stage IIIC | 72 (10.6) | 19 (11.3) | 16 (11.0) | 12 (8.3) | 11 (11.1) | 0 (0.0) | 14 (15.9) |
 Stage IV | 457 (67.0) | 135 (80.4) | 74 (50.7) | 128 (88.3) | 69 (69.7) | 34 (94.4) | 17 (19.3) |
Current TNM staging, n (%) | 682 | 168 | 146 | 145 | 99 | 36 | 88 |
 Stage IIIA | 37 (5.4) | 1 (0.6) | 15 (10.3) | 1 (0.7) | 8 (8.1) | 0 (0.0) | 12 (13.6) |
 Stage IIIB | 68 (10.0) | 8 (4.8) | 21 (14.4) | 1 (0.7) | 8 (8.1) | 0 (0.0) | 30 (34.1) |
 Stage IIIC | 78 (11.4) | 19 (11.3) | 15 (10.3) | 11 (7.6) | 10 (10.1) | 1 (2.8) | 22 (25.0) |
 Stage IV | 499 (73.2) | 140 (83.3) | 95 (65.1) | 132 (91.0) | 73 (73.7) | 35 (97.2) | 24 (27.3) |
De novo vs recurrent disease, n (%) | 682 | 168 | 146 | 145 | 99 | 36 | 88 |
 De novo | 552 (80.9) | 151 (89.9) | 107 (73.3) | 138 (95.2) | 87 (87.9) | 32 (88.9) | 37 (42.1) |
 Recurrent | 130 (19.1) | 17 (10.1) | 39 (26.7) | 7 (4.8) | 12 (12.1) | 4 (11.1) | 51 (58.0) |